From November 13 to 16, 2023 Dusseldorf International Medical and Medical Device Fair (MEDICA) was held in Dusseldorf Exhibition Center, Germany. As the world's top comprehensive medical equipment exhibition, MEDICA 2023 ranks first among similar international exhibitions in terms of scale and influence. As a leading enterprise of brain diagnosis and treatment equipment in China, Delica brought a number of clinical overall solutions to more than 5,500 enterprises from more than 70 countries and regions around the world to jointly display innovative products and services.
As a "regular visitor" to the MEDICA exhibition, Delica has been welcoming visitors from all over the world in Pavilion 9, which is at the core of the exhibition for nearly 20 years. In this exhibition, Delica brought a variety of products such as multifunctional vascular ultrasound device (MVU), transcranial Doppler blood flow analyzer (TCD), digital multifunctional electroencephalogram (EEG) and noninvasive cerebral blood oxygen monitor (NIRS), which were independently developed and produced. Delica provided one-stop brain health solutions, attracting many visitors to consult and understand its products.
On this occasion, Delica representatives had extensive exchanges with distributors and hospital representatives from many countries such as the United States, Germany, Canada, France, Spain, Italy, and the Netherlands. Partners from all over the world expressed their appreciation for Delica's continuous and remarkable achievements in products and markets over the years. The clinical value, market prospect and cooperation mode of new products, new technologies and new applications were discussed in depth. Especially for Delica's newly launched "3D Scan automatic probe technology", "wireless portable blood flow monitoring technology", "non-invasive hemodynamic comprehensive monitoring technology", "full digital QEEG brain function diagnosis technology", they have expressed strong interest and promotion intention, and expressed great confidence in its market prospect.
Professor Ruud Keunen of the Hague School of Medicine has shown that: "TCD and NIRS have a good correlation in predicting ischemia, and they are often used together during surgery. The sensitivity and specificity of NIRS in monitoring intraoperative cerebral hypoperfusion are highly consistent with the results of TCD monitoring. "Therefore, NIRS can be used for intraoperative monitoring in patients who cannot use TCD due to temporal window limitations."
Based on the powerful signal acquisition and analysis ability of intelligent ultrasound transcranial Doppler blood flow analyzer (TCD) EMS-9D, TCD and cerebral oxygen related parameters were displayed and analyzed simultaneously on the same screen. Comprehensive monitoring of brain function can provide a variety of physiological parameters, improve the sensitivity of monitoring and prognosis during operation, which is a more popular monitoring mode. In addition, the combined application of transcranial Doppler and cerebral oxygen monitoring can effectively reflect the state of cerebral blood flow and oxygen metabolism during selective cerebral perfusion under deep hypothermic circulatory arrest, which has important guiding significance for the adjustment of cerebral perfusion flow during selective cerebral perfusion under deep hypothermic circulatory arrest.
Delica cerebral blood flow autoregulation solution integrates cerebral blood flow velocity signal acquisition and non-invasive continuous blood pressure signal monitoring in one. It is the output result of "Digital cerebral blood flow reserve function diagnosis and evaluation technology and its application Research", a key research and development plan of the Ministry of Science and Technology of the People's Republic of China. The phase, gain and coherence can be calculated online to qualitatively and quantitatively analyze the cerebral blood flow autoregulation function of patients, and the ARI index and Mx a index of cerebral blood flow autoregulation can be obtained. The analysis report of cerebral blood flow autoregulation can be output, and the data can be exported to meet the needs of scientific research.
Delica has been deeply engaged in the research and development of medical devices for 25 years. Delica has always focused on the research and development and production of products for the diagnosis and treatment of brain diseases in the field of brain science, insisting on independent research and development, breaking through technical difficulties and breaking down a number of core technical barriers. At present, Delica has formed a combination of technology solutions for the diagnosis and monitoring of stroke, epilepsy, neurological critical illness, syncope and other diseases. Up to now, Delica has obtained more than 100 domestic and foreign patents, and has successively won the honorary certification of "National specialized and Special New small Giant Enterprise" and "Guangdong Brain Ultrasound Engineering Technology Research Center". Relying on its strong scientific research strength and excellent product quality, Delica has won wide praise from the industry.
The appearance of MEDICA 2023 undoubtedly opens a new window for Delica's global branding and product presentation. In the process of internationalization, Delica has always adhered to its own brand to go abroad, through the research and development of high-quality products to meet the needs of clinical use in different markets. Now, Delica has accumulated cooperation with more than 1000 hospitals around the world, serving more than 30 countries and regions around the world. In the future, Delica will continue to adhere to the internationalization strategy, strengthen strategic cooperation with international partners, promote Chinese medical devices to the world, and make greater contributions to the development of global medical cause.